ERBB2 and non-small cell lung carcinoma: The introduction of antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan for <i>HER2</i>-mutant NSCLC, and emerging TKIs like zongertinib, represent new therapeutic milestones.